Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay

Gustavo Echeverría, Ángel Guevara, Josefina Coloma, Alison Mera Ruiz, María Mercedes Vasquez, Eduardo Tejera, Jacobus H. de Waard

*Instituto de Investigación en Zoonosis-CIZ, Universidad Central del Ecuador, Ecuador
b Instituto de Biomedicina, carrera de Medicina, Universidad Central, Quito, Ecuador
c Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
d BioGENA, División Investigación y Desarrollo, Quito, Ecuador
*One Health Research Group, Facultad de Ciencias de la Salud, Universidad de Las Américas (UDLA), Quito, Ecuador

**A R T I C L E   I N F O**

Article history:
Received 3 January 2021
Received in revised form 1 February 2021
Accepted 7 February 2021

Keywords:
Pre-existing immunity
COVID-19
SARS-CoV-2
T cells
Interferon-Gamma (IFN-γ) release assay (IGRA)
ELISPOT
Spike protein
Nucleocapsid protein

**A B S T R A C T**

**Background:** Studies of T-cell immune responses against SARS-CoV-2 are important in understanding the immune status of individuals or populations. Here, we use a simple, cheap, and rapid whole blood stimulation assay – an Interferon-Gamma Release Assay (IGRA) – to study T-cell immunity to SARS-CoV-2 in convalescent COVID-19 patients and in unexposed healthy contacts from Quito, Ecuador.

**Methods:** Interferon-gamma (INF-γ) production was measured in the heparinized blood of convalescent and unexposed subjects after stimulation for 24 h with the SARS-CoV-2 Spike S1 protein, the Receptor Binding Domain (RBD) protein or the Nucleocapsid (NP) protein, respectively. The presence of IgG-RBD protein antibodies in both study groups was determined with an “in-house” ELISA.

**Results:** As measured with INF-γ production, 80% of the convalescent COVID-19 patients, all IgG-RBD seropositive, had a strong T-cell response. However, unexpectedly, 44% of unexposed healthy controls, all IgG-RBD seronegative, had a strong virus-specific T-cell response with the COVID-19 IGRA, probably because of prior exposure to common cold-causing coronaviruses or other viral or microbial antigens.

**Conclusion and Discussion:** The high percentage of unexposed healthy subjects with a pre-existing immunity suggests that a part of the Ecuadorian population is likely to have SARS-CoV-2 reactive T-cells. Given that the IGRA technique is simple and can be easily scaled up for investigations where high numbers of patients are needed, this COVID-19 IGRA may serve to determine if the T-cell only response represents protective immunity to SARS-CoV-2 infection in a population-based study.

© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Introduction**

The immune response to SARS-CoV-2 infection involves not only antibody production, but the infection also triggers a T-cell response in patients (Lipsitch et al., 2020, Ni et al., 2020). In general, the determination of the presence and magnitude of a specific memory T-cell response to this coronavirus infection is performed with an ELISPOT assay by establishing the number of lymphocytes that produce IFN-γ after stimulation with disease-specific antigens or peptides (Ni et al., 2020, Pai et al., 2014, Abate et al., 2013, Braun et al., 2020, Grifono et al., 2020, LeBert et al., 2020, Sekine et al., 2020). For this technique, peripheral blood mononuclear cells (PBMCs) are isolated from fresh heparinized blood by density-gradient centrifugation; the secretion of cytokines by individual T-cells is quantified by microscopy or with a special apparatus– the ELISPOT plate reader. The ELISPOT assay is a “for research laboratories only” technique that is highly laborious, technically demanding, relatively expensive, and cannot easily be used in a clinical laboratory or be applied in population-based studies. Due to the cost, infrastructure, and the laboratory
requirements needed to perform the assay, its use in resource-
limited settings such as Ecuador may be minimal.

Cellular immune responses can also be determined with a more
straightforward assay: an interferon-gamma release assay (IGRA).
This assay, an *in vitro* blood test, quantifies T-cell secreted cytokines
(i.e., gamma interferon [IFN-γ]; however, other cytokines like TNFα
or IL-2 can also be quantified) upon stimulation of the whole blood
(not just the isolated lymphocytes) with specific antigens (Pai et al.,
2014, Abate et al., 2013). The secreted cytokine IFN-γ is measured
with an ELISA assay, a readily available technique in most
laboratories, and the results are read out with an ELISA plate
reader. IGRAs have found an application in the clinical laboratory
and are used to determine a latent infection with *Mycobacterium
tuberculosis* (MTB) as well as to measure cytomegalovirus (CMV)-
specific cell-mediated immunity and predict CMV infection in
transplant recipients (Pai et al., 2014, Abate et al., 2013). These IGRA
tests have been extensively evaluated and, compared with the
ELISPOT assay, have been shown to display similar capabilities for
predicting MTB or CMV infection. Moreover, several commercial
and FDA or CE marked assays to detect immunity against TB or CMV
are available and are widely performed.

In the present study, we explore the use of a COVID-19 IGRA and
assess the magnitude of IFN-γ release in convalescent COVID-19
patients and healthy COVID-19 naive controls in response to
specific antigens of the SARS-CoV-2 virus: the RBD protein; the S1
part of the Spike protein; or the Nucleocapsid (N) protein.
Additionally, we determine the presence of SARS-CoV-2 specific
IgG antibodies in those participants with an “in-house” ELISA
(Amanat et al., 2020, Guevara et al., 2021). We show that a
significant percentage of unexposed donors possess SARS-CoV-2
reactive T-cells, and we discuss these results.

**Material and methods**

**Convalescent COVID-19 patients, healthy controls, and the setting**

This study was conducted in Quito, Ecuador, in September 2020.
No statistical methods were used to predetermine the sample size.
Table 1 shows the characteristics of the 32 patients in this study:
thirteen convalescent COVID-19 patients, all with non-severe
COVID-19 symptoms/signs and a positive RT-PCR diagnosis in June
2020; and 17 unexposed healthy controls. These healthy controls
had been extremely cautious during the pandemic, avoiding
contact with other people and self-reported none of the typical
signs and symptoms of COVID-19 for the duration of the pandemic,
such as fever, a persistent cough, or a loss of smell or taste. Also,
two asymptomatic SARS-CoV-2 carriers were included in this
study. These two subjects never showed any symptoms or signs of
COVID-19 disease; however, the RT-PCR technique was carried out
on them as a requirement for a work permit in June 2020 and
resulted in positive diagnoses.

| Table 1 | Demographic and diagnostic characteristics of the convalescent COVID-19 patients and healthy controls. |
|-----------------------------------------------|
| Subjects n = 33 | Male / Female Ratio | Mean age (SD) | RT-PCR positive | COVID-19 related symptoms and signs | RBD serodiagnosis | T-cell response positive |
| 13 convalescent patients | 10/3 | 34 (8.0) | 13/13 | I3 | 13/13 Positive | 10/13 (77%) |
| 2 asymptomatic patients | 1/1 | 32 (2.1) | 2/2 | None | Negative | 2/2 (100%) |
| 17 healthy controls | 8/9 | 40 (12.8) | None | None | Negative | 8/17 (47%) |

Thirty-two subjects were included in this study: thirteen RT-PCR positive patients with clinical signs and symptoms of COVID-19, two asymptomatic RT-PCR positive patients, and 17 healthy COVID-19-naïve patients. All COVID-19 patients had at least three of the five most common signs or symptoms of COVID-19: fever, respiratory problems, loss of smell/taste, and fatigue. They were positive for serology with an “in-house” SARS-CoV-2 Receptor Binding Domain (RBD) IgG ELISA (5, 6). No severe clinical cases were admitted in this study, and patients were all treated at home. The 17 healthy controls and the two asymptomatic RT-PCR positive subjects reported no signs or symptoms of COVID-19 or other health-related problems since the COVID-19 outbreak in Ecuador in March 2020, and all 19 were negative for RBD-IgG serology. All convalescent patients were tested three months after their positive RT-PCR.

**Serology**

Serology and IGRAs for all patients and controls were
performed during the last two weeks of September 2020, three
months after the RT-PCR diagnosis of the convalescent patients. To
determine the presence of coronavirus-specific IgG antibodies in
our study group, an “in-house” SARS-CoV-2 Receptor Binding
Domain (RBD) IgG ELISA (9, 10) was used.

**Interferon Gamma Release Assay (IGRA)**

For the IGRA, a heparinized blood sample was taken (4 mL) and
divided into aliquots of 250 μL and stimulated with respectively 2
μg/mL of the RBD protein (isolation procedure from reference 9) or
2 μg/mL of the commercially available Nucleocapsid (N) protein or
Spike (S1) protein (ViroGen, www.virogen.com, Catalog Numbers:
00,221-V and 00,226-V respectively). A dose concentration-
response curve with blood from IGRA positive and IGRA negative
patients was used to determine the antigens’ optimum concentration
for stimulation in the IGRA. At 2 μg/mL, a maximum IFN-γ response
in blood from COVID-19 subjects was found without stimulation in
the uninfected controls. For each participant, an unstimulated control
(NIL) was included, and we assayed a 250 μL blood sample with the
mitogen phytohaemagglutinin (PHA), a positive control to assess the
cytokine response rate of the blood sample. Stimulation was realized in a
96-well flat-bottom ELISA plate at 37 °C for 24 h. Plasma was harvested, and IFN-γ production was determined with a Human IFN-γ ELISA (MaxTM Standard Set Biologend cat. No. 430,101).

**Results**

The RBD IgG ELISA showed that all COVID-19 symptomatic
patients (RT-PCR positive) were positive for IgG antibodies against
the RBD protein three months after the RT-PCR diagnosis. The two
asymptomatic RT-PCR positive patients and all healthy unexposed
control patients were seronegative with this ELISA (See Table 1).
The results of whole blood stimulation in the COVID-19 IGRA assay
are shown in Figure 1. Strong induction of IFN-γ production was
found in 80% of the COVID-19 symptomatic patients with all three
antigens, but the N protein and S protein were the most potent
stimulators of an IFN-γ response (Figure 1 A, B, C). The two
asymptomatic but RT-PCR positive patients (patient 14 and 15),
both without specific SAR-CoV-2 antibodies, also showed a strong
inducible T-cell immunity response. Of the COVID-19 naïve
patients, 45% showed inducible T-cell immunity. The response in
these healthy unexposed controls with a T-cell response was
statistically not significantly different in magnitude from the
convalescent COVID-19 patients for any of the stimulating antigens
(p-value = 0.271, 0.437, and 0.719 for RBD, N, and S1 proteins,
respectively).
Discussion and conclusions

Using an easy-to-perform whole blood assay that assesses T-cell responses, we found that most convalescent patients and a significant proportion of healthy unexposed individuals had a specific and strong T-cell response determined with the production of INF-γ after stimulation with SARS-CoV-2 specific antigens (Figure 1). Several studies, all using the ELISPOT assay, have reported the presence of a T-cell response in most or all convalescent COVID-19 patients (Braun et al., 2020, Grifoni et al., 2020, LeBert et al., 2020, Sekine et al., 2020, Moderbacher et al., 2020, Mateus et al., 2020, Peng et al., 2020). However, concerning a T-cell response in healthy unexposed controls, response rates between 28 and 50% have been reported (Doshi, 2020, de Vries, 2020, Lipsitch et al., 2020, Sagar et al., 2020), and several studies report no T-cell response in COVID-19 naïve control patients (de Vries, 2020, Moderbacher et al., 2020, Schwarzkopf et al., 2021). Most of these studies were performed with the ELISPOT assay, but in Italy and the USA, an IGRA has also been used to detect the SARS-CoV-2 T-cell response (Petrone et al., 2020, Murugesan et al., 2020). In both studies, a specific T-cell response was detected in convalescent patients; however, the IGRA did not detect an INF-γ response in healthy unexposed subjects.

Pre-existing T-cell immunity to SARS-CoV-2 in COVID-19 naïve subjects has been reviewed in several publications (Altmann and Boyton, 2020, Dosho et al., 2020, de Vries, 2020, Sette and Crotty, 2020). The reason why a specific COVID-19 T-cell response might be detected in a healthy unexposed subject remains unclear and is the subject of speculation. Most ELISPOT studies with COVID-19 naïve subjects used human blood samples derived before the SARS-CoV-2 virus was discovered in 2019, thus before any chance of exposure. For this reason, these ELISPOT studies concluded that the T-cell response in unexposed healthy subjects probably comes from prior contact with circulating “common cold” coronaviruses (Grifoni et al., 2020, Matheus et al., 2020) or previous exposure to flu and/or CMV viruses (Mahajan et al., 2020) or other viral or microbial antigens (Tan et al., 2020). Our study used blood taken during the pandemic from volunteers who self-reported zero contact, were seronegative for the COVID-19 antigen RBD, and had never shown any signs or symptoms of COVID-19. Therefore we cannot exclude that the T-cell response in some of our COVID-19 “naïve” healthy controls comes from asymptomatic SARS-CoV-2 virus infections. Patients 14 and 15 of our study are an example of this. These individuals were classified as COVID-19 patients because of a positive RT-PCR; however, they were asymptomatic and did not develop an antibody response against the RBD protein, but both showed a strong T-cell response. It is possible that, after SARS-CoV-2 colonization of the nasopharynx, the immune system of these two asymptomatic patients left them with a memory T-cells-only response, and no SARS-CoV-2 specific antibodies were
induced. Another explanation is that the T-cell response comes from a previous corona-like infection, and the pre-existing T-cell immune response protected these two patients against the development of a more invasive disease pattern. Pre-existing cross-reactive T-cells could be significant in explaining some of the differences in infection rates or pathology (Le Bert et al., 2020, Sagar et al., 2020). Concerning the cohort of naïve controls, we excluded that this group contains a considerable number of SARS-CoV-2 infected individuals with undetected asymptomatic infection, basically because all the integrands of the control group are IgG seronegative for the RBD antigen. Another reason is that the infection prevalence in Ecuador is relatively low. At the time of this study, September 2020, Ecuador had reported about 200,000 confirmed COVID-19 cases (about 1.1% of the population). Of course, the actual infection prevalence could have been several times higher, but even so, it is improbable that 45% of this control group got infected, and thus that we are looking at a T-cell response specific for a SARS-CoV-2 infection.

In conclusion, the finding of a high percentage of unexposed healthy subjects with a pre-existing immunity in Quito, Ecuador, raises the expectation that a significant part of our population is likely to have SARS-CoV-2 reactive T-cells because of prior exposure to flu, CMV viruses, or common cold-causing coronaviruses. Future investigations should aim to determine whether the pre-existing immune response is protective and/or can overcome a more severe COVID-19 disease or contributes to a faster recovery.

Importance and limitation of this study

Our study showed that the COVID-19 IGRA is a useful and sensitive new tool that can assess exposure to coronaviruses or cross-reactivity to similar viruses by determining the release of IFN-γ after stimulation with virus-specific antigens. The technique is simple, relatively cheap, and can be used in a clinical laboratory. This is certainly not the case with the ELISPOT assay. Moreover, the IGRA assay can be easily scaled up for population-based studies and investigations where high numbers of patients are required. Together with serology, the IGRA can be used to screen both antibody and T-cell responses of individual patients to better understand population-level immunity and determine pre-existing immunity in seronegative individuals.

An important limitation of our study is that the study sample is not representative of the population. No statistical methods were used to predetermine the sample size. Furthermore, our assay didn’t differentiate between IFN-γ production of CD4+ or CD8+ cells, but stimulation with defined CD8(+) and CD4(+) peptides can be considered (Grifoni et al., 2020, Peng et al., 2020) and has been used in the IGRA described in Petrone et al., 2020 and Murugesan et al., 2020). Also, the induction of other cytokines can be measured with this IGRA (Petrone et al., 2020). Likewise, the IGRA can be employed for follow-up on vaccination to determine the development of the T-cell response in vaccinated individuals or can be used to determine if the presence of cross-reactive memory T-cells is associated with protective immunity and can diminish the disease manifestations from SARS-CoV-2 infection (Sagar et al., 2020).

Ethics approval and participation consent

Blood was collected following informed written consent. The Ethics Committee of the Health Ministry of Ecuador approved the study protocol 004–2020.

Conflict of interests

The authors declare that they have no competing interests.
following COVID-19. Nat Immunol 2020, doi:http://dx.doi.org/10.1038/s41590-020-0782-6.

Petrone L, Petruccioli E, Vanini V, Cuzzi G, Fard SN, Alonzi T, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect 2020, doi:http://dx.doi.org/10.1016/j.cmi.2020.09.051 09 October. accepted for publication.

Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White L, et al. Recent endemic coronavirus infection is associated with less severe COVID-19. J Clin Invest 2020, doi:http://dx.doi.org/10.1172/JCI143380.

Schwarzkopf S, Krawczyk A, Knop D, Klump H, Heinold A, Heinemann FM, et al. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed infection but with undetectable SARS-CoV-2-Specific IgG. Emerg Infect Dis. 2021;27(1), doi:http://dx.doi.org/10.3201/2701203772.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183(1)158–68, doi:http://dx.doi.org/10.1016/j.cell.2020.08.017 e14.

Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. 2020;20(8)457–8, doi:http://dx.doi.org/10.1038/s41577-020-0389-z Erratum in: Nat Rev Immunol. 2020;20(10):644.

Tan CCS, Owen CJ, Tham CYL, Bertoletti A, van Dorp L, Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. bioRxiv 2020:2020. doi:http://dx.doi.org/10.1101/2020.12.08.415703 12.08.415703.